Table IV.
Parvovirus B19 infection and clinicopathological variables.
| B19 DNAa | |||
|---|---|---|---|
| Variables | Positive (%) | Negative (%) | P-valueb |
| Total patient sample | 66 (42.3) | 90 (57.7) | |
| Male | 47 (42.7) | 63 (57.3) | 0.8697 |
| Female | 19 (41.3) | 27 (58.7) | |
| Cancer category | |||
| Lung | 30 (56.6) | 23 (43.4) | 0.0095 |
| Breast | 6 (31.6) | 13 (68.4) | 0.3125 |
| Stomach | 9 (56.2) | 7 (43.8) | 0.2334 |
| Liver | 5 (31.3) | 11 (68.7) | 0.4978 |
| Prostate | 6 (46.2) | 7 (53.8) | 0.7694 |
| Intestinal | 5 (29.4) | 12 (70.6) | 0.2542 |
| Renal | 1 (20.0) | 4 (80.0) | 0.3969 |
| Other malignanciesc | 4 (23.5) | 13 (76.5) | 0.1217 |
a
Reported as the number (percentage) of patients, unless otherwise indicated.
b
χ2 test, Fisher’s exact test or the t-test.
c
Other malignancies: lymphoma, nasopharyngeal cancer, hepatocellular carcinoma, germ cell tumor, esophageal cancer, uterus carcinoma, pancreatic cancer, cancer of the larynx, brain metastases cancer, bladder carcinoma, mediastinal mass and endometrial cancer.